23/09/2024 – AB Science today provides an update on the development of masitinib in progressive forms of multiple sclerosis (MS), following the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 conference
08/07/2024 – AB Science today announces the results of a Phase 2 study evaluating masitinib in COVID-19
28/06/2024 – AB Science today announces that the CHMP has adopted, in line with the trend vote, a negative opinion on the application for conditional marketing authorization of masitinib in the treatment of ALS
26/06/2024 – Q&A document of the June 26, 2024 Combined General Meeting
31/05/2024 – AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
30/05/2024 – Presentation of the AB Science webcast held on May 30, 2024
29/05/2024 – AB Science today announces that the CHMP adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in ALS
17/05/2024 – AB Science communicates a corrective statement on the consolidated accounts as of December 31, 2023
15/05/2024 – AB Science reports its revenues for the year 2023 and provides an update on its activities
13/05/2024 – AB Science today announced that the European patent office has issued a Grant Decision for a patent relating to methods of treating severe mastocytosis with its lead compound masitinib